RegenX Bio Gene Therapy Shows Early Promise In Macular Degeneration [Forbes]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Forbes
Shutterstock A gene therapy being developed by RegenX Bio of Rockville, MD, showed early promise against wet macular degeneration, a leading cause of blindness. The drug seeks to replace existing drugs that are injected into the eye regularly to prevent a build up of fluid that damages the retina. These medicines, including Roche's Avastin and Lucentis and Regeneron's Eylea, block a protein called the vascular endothelial growth factor (VEGF), which causes blood vessel growth. A virus, called adeno-associated virus (AAV), is used to insert a gene for a protein much like Lucentis into the eye. The idea is that this will lead to levels of anti-VEGF protein that are similar to what one gets from injecting a drug. But previous attempts, including one funded by the drug giant Sanofi, have been unsuccessful. This is the first time we're getting to that level, says Dr. Peter Campochiaro the Eccles Professor of Opthamology and Neuroscience at Johns Hopkins Universit
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia [Yahoo! Finance]Yahoo! Finance
- Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaGlobeNewswire
- A once-unthinkable revolution is quietly sweeping France's corporate landscape: Foreign-born CEOs [Fortune]Fortune
- Sanofi reportedly settles 4K Zantac cases for $100M [Seeking Alpha]Seeking Alpha
- Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 2/12/24 - TheStreet
SNY
Sec Filings
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- 3/20/24 - Form 6-K
- SNY's page on the SEC website